Home / News and media / Stock exchange releases / Archive / 2008

2008

Dec 11th 2008 10:24 AM Stock Exchange Release

Orion comments on ANDA filed by Wockhardt Limited for a generic version of Orion's proprietary drug Stalevo® (25/200/100; 37.5/200/150 and 50/200/200 mg strengths) in the United States
Dec 8th 2008 8:47 PM Stock Exchange Release

Orion sues Wockhardt USA, Inc. and Wockhardt Limited in the U.S. to enforce Orion's U.S. Patents covering its proprietary drug Stalevo®
Nov 19th 2008 9:13 AM Stock Exchange Release

Orion to renew operational model of pharmaceutical R&D. Negotiation proposal on reduction of up to 300 employees in Finland
Nov 12th 2008 9:16 PM Stock Exchange Release

Orion sues Sun Pharma Global, Inc. in the U.S. to enforce Orion's U.S. Patent No. 5,446,194 covering its proprietary drug Comtan®
Nov 3rd 2008 8:30 AM Stock Exchange Release

Orion comments on ANDA filed by Wockhardt Limited for a generic version of Orion's proprietary drug Stalevo® in the United States
Oct 29th 2008 4:48 PM Stock Exchange Release

Composition of the Nomination Committee of Orion Corporation
Oct 28th 2008 8:40 AM Stock Exchange Release

Orion Corporation's publication schedules for financial reporting in 2009
Oct 28th 2008 8:30 AM Stock Exchange Release

Orion Group Interim Report 1-9/2008
Oct 7th 2008 7:14 PM Stock Exchange Release

Orion comments on new ANDA by Sun Pharma Global, Inc. for generic entacapone (Orion's proprietary drug Comtan®) in the United States
Sep 12th 2008 12:34 PM Stock Exchange Release

Orion updates progress with dexmedetomidine trials
Aug 5th 2008 12:00 PM Stock Exchange Release

Orion Group Interim Report 1-6/2008
Jul 23rd 2008 10:00 AM Stock Exchange Release

Orion Corporation publishes Interim Report Q2/2008 on 5 August 2008
May 9th 2008 1:20 PM Stock Exchange Release

Orion has decided not to continue the development of a new COMT inhibitor candidate
Apr 25th 2008 11:59 AM Stock Exchange Release

Orion Group Interim Report 1-3/2008
Apr 15th 2008 9:30 AM Stock Exchange Release

Orion seeking broader indication for Stalevo
Mar 25th 2008 4:20 PM Stock Exchange Release

Orion Corporation: Jukka Ylppö Vice Chairman of the Board of Directors. Compositions of Board committees
Mar 25th 2008 4:12 PM Stock Exchange Release

Orion Corporation: Decisions by the AGM on 25 March 2008
Feb 28th 2008 11:13 AM Stock Exchange Release

Orion Group Annual Report 2007 published
Feb 25th 2008 1:00 PM Stock Exchange Release

ORION OYJ: GTx ANNOUNCED PHASE III CLINICAL DATA FOR TOREMIFENE CITRATE 80 mg
Feb 7th 2008 11:37 PM Stock Exchange Release

Orion sues Sun Pharmaceuticals in the U.S. to enforce Orion's U.S. Patent No. 5,446,194 covering its proprietary drug Stalevo®
Feb 7th 2008 9:36 AM Stock Exchange Release

Orion: Annual Summary of Stock Exchange Releases and Announcements published in 2007
Feb 7th 2008 8:45 AM Stock Exchange Release

Matters to be handled at Orion's AGM on 25 March 2008
Feb 7th 2008 8:30 AM Stock Exchange Release

Orion Group Financial Review of 2007
Jan 30th 2008 4:30 PM Stock Exchange Release

Recommendation by the Nomination Committee concerning Board of Directors to be elected by the AGM of Orion Corporation
Jan 24th 2008 3:00 PM Stock Exchange Release

Positive primary endpoint from FIRST-STEP study with Stalevo in early Parkinson's Disease
Jan 2nd 2008 8:45 AM Stock Exchange Release

Orion comments on new challenge by Sun Pharmaceutical Industries Ltd., India, of Orion's U.S. Patent No. 5,446,194 covering its proprietary drug Stalevo® in the United States

2008

Orion comments on ANDA filed by Wockhardt Limited for a generic version of Orion's proprietary drug Stalevo® (25/200/100; 37.5/200/150 and 50/200/200 mg strengths) in the United States

Orion sues Wockhardt USA, Inc. and Wockhardt Limited in the U.S. to enforce Orion's U.S. Patents covering its proprietary drug Stalevo®

Orion to renew operational model of pharmaceutical R&D. Negotiation proposal on reduction of up to 300 employees in Finland

Orion sues Sun Pharma Global, Inc. in the U.S. to enforce Orion's U.S. Patent No. 5,446,194 covering its proprietary drug Comtan®

Orion comments on ANDA filed by Wockhardt Limited for a generic version of Orion's proprietary drug Stalevo® in the United States

Composition of the Nomination Committee of Orion Corporation

Orion Corporation's publication schedules for financial reporting in 2009

Orion Group Interim Report 1-9/2008

Orion comments on new ANDA by Sun Pharma Global, Inc. for generic entacapone (Orion's proprietary drug Comtan®) in the United States

Orion updates progress with dexmedetomidine trials

Orion Group Interim Report 1-6/2008

Orion Corporation publishes Interim Report Q2/2008 on 5 August 2008

Orion has decided not to continue the development of a new COMT inhibitor candidate

Orion Group Interim Report 1-3/2008

Orion seeking broader indication for Stalevo

Orion Corporation: Jukka Ylppö Vice Chairman of the Board of Directors. Compositions of Board committees

Orion Corporation: Decisions by the AGM on 25 March 2008

Orion Group Annual Report 2007 published

ORION OYJ: GTx ANNOUNCED PHASE III CLINICAL DATA FOR TOREMIFENE CITRATE 80 mg

Orion sues Sun Pharmaceuticals in the U.S. to enforce Orion's U.S. Patent No. 5,446,194 covering its proprietary drug Stalevo®

Orion: Annual Summary of Stock Exchange Releases and Announcements published in 2007

Matters to be handled at Orion's AGM on 25 March 2008

Orion Group Financial Review of 2007

Recommendation by the Nomination Committee concerning Board of Directors to be elected by the AGM of Orion Corporation

Positive primary endpoint from FIRST-STEP study with Stalevo in early Parkinson's Disease

Orion comments on new challenge by Sun Pharmaceutical Industries Ltd., India, of Orion's U.S. Patent No. 5,446,194 covering its proprietary drug Stalevo® in the United States

Archive

2012

2011

2010

2009

2008

2007

2006